Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470

J Neurooncol. 1995;23(1):23-9. doi: 10.1007/BF01058456.

Abstract

Meningiomas are relatively common (22%) vascular brain tumors. 3-11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating these hypervascular tumors. Inhibition of tumor-induced angiogenesis by TNP-470 (previously termed AGM-1470), a synthetic analogue of fumagillin, was tested on the growth of human non-malignant and malignant meningiomas in nude mice. TNP-470 significantly inhibited tumor neovascularization and tumor growth of both non-malignant and malignant meningiomas. TNP-470 is now in human trial and should be tested for efficacy in treating malignant or recurrent aggressive meningiomas.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / therapeutic use*
  • Body Weight / drug effects
  • Cell Transplantation
  • Cyclohexanes
  • Female
  • Humans
  • Meningeal Neoplasms / blood supply
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / pathology
  • Meningioma / blood supply
  • Meningioma / drug therapy*
  • Meningioma / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Neurofibromatoses / drug therapy
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Regional Blood Flow / drug effects
  • Sesquiterpenes / therapeutic use*
  • Transplantation, Heterologous

Substances

  • Antibiotics, Antineoplastic
  • Cyclohexanes
  • Sesquiterpenes
  • O-(Chloroacetylcarbamoyl)fumagillol